RE: Global Health Investment Fund I, LLC (GHIF) investment in GDR16 Jun 2020 17:08
Genedrive 96 SARS-CoV-2 Summary Friday 12 June - Sales this month
Presentation Title
Huge market potential and currently limited price sensitivity
• Unique product design with meaningful, valuable benefits to the user
• Top tier clinical performance specifications
• Temperature stable nature facilitates global distribution to global markets
• Competitive pricing with attractive margins
• Commercial scale manufacturing capability with Cytiva
• Distribution routes established and even more being established
• CE Marking achieved, additional registrations in process
• Global pandemic continues to grow, making global distribution capability important
• COVID-19 can only be controlled through constant monitoring (testing), social distancing,
and treatment (vaccine)
• Company anticipates recording first sales this month.